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According to the latest cancer statistics from the South African (SA) 
National Cancer Registry 2010, breast cancer is ranked as the most 
common cancer in women (20.62%), with an overall lifetime risk of 
developing breast cancer of 1 in 35 women.[1]
Increasing age remains the largest single risk factor for the 
development of breast cancer.[2] Despite this significant association, 
breast cancer survivors diagnosed at ≥65 years of age represent an 
understudied population in cancer research, with age and comorbid 
chronic conditions the primary reasons for their exclusion from 
clinical trials.[3] Conventionally, elderly has been defined as a 
chronological age of ≥65 years.[4] To date, no data exist in SA on the 
incidence of breast cancer in the elderly population. 
Furthermore, post-treatment follow-up practices are not well known. 
Current surveillance programmes are adopted from the American 
Society of Clinical Oncology, which recommends regular clinical 
assessment and annual mammographic surveillance to detect disease 
relapse.[5] No cut-off age for following up these patients has been defined. 
Because of the increased risk of developing a second primary breast 
cancer and the risk of relapse, this screening protocol has been shown 
to be a cost-effective tool internationally, with adequate surveillance 
associated with improved survival and decreased mortality.
Despite the acknowledged rationale for annual surveillance 
mammograms, a study by Doubeni et al.[6] demonstrated a decline 
from 80.0% to 63.0% in the use of mammography among breast 
cancer survivors over a 5-year period, especially in older women with 
comorbid illnesses or those with late-stage disease. 
The lack of data on the incidence, post-treatment surveillance practices 
and breast cancer relapse rates in the elderly SA population poses a chal-
lenge to providing optimum follow-up care for breast cancer survivors. 
Surveillance breast imaging regimens and intervals are adopted from 
international guidelines, which has implications for healthcare utilisa-
tion, cost and mortality. Knowledge of relapse-specific intervals aids in 
focusing surveillance at these identified periods, allows early detection 
of recurrence, and assists in promoting improved health awareness for 
our patients. Understanding relapse rates in the elderly patient also has 
important consequences for treatment practices, particularly in a popu-
lation where morbidity from ageing and comorbid conditions assumes a 
greater impact on lifestyle, adherence practices and prognosis. 
Objectives
The objective of our study was to assess the effect of breast cancer 
on elderly SA patients. To date, no research on this subject has 
been undertaken locally. By assessing follow-up practices and post-
treatment mammographic findings, it is hoped that the currently 
accepted international surveillance protocols may be reviewed and, 
if necessary, adapted to better suit the SA experience of the disease.
Methods 
A retrospective review was undertaken of all patients with histologi-
cally proven breast cancer diagnosed at ≥65 years of age, attending the 
breast oncology clinics at Addington and Inkosi Albert Luthuli Central 
hospitals, Durban, KwaZulu-Natal, SA during the defined study time 
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period. Patients diagnosed with breast can-
cer between January and December 2007 
were entered into the study and followed up 
for a 5-year interval from January 2008 to 
December 2012.
Of the 150 patients diagnosed with breast 
cancer during 2007, 40 were ≥65 years of age. 
Of the 40 women eligible for the study, one was 
excluded owing to the presence of a second 
malignancy, diagnosed within 5 years of inci-
dent breast cancer diagnosis. A complete data-
set was not obtained for a further 7 patients, 
who were also excluded. Thirty-two patients 
were included in the final analysis. 
Data were extracted from patient charts 
retrospectively. Study numbers were used 
instead of patient identifiers during data 
collection, analysis and presentation of results 
to maintain patient anonymity. Information 
with regard to gender, age at diagnosis, stage 
of index breast cancer, and treatment received 
were recorded from the surgical breast clinic 
files. Patients were then followed up at the 
oncology clinics after treatment, where data 
on surveillance with annual mammograms, 
new mammographic findings, site of recur-
rence, mode of detection of recurrence, and 
survival outcome were recorded. Patients 
who had defaulted on their follow-up clinic 
appointments were contacted telephonically 
to assess survival outcome. Family members 
were contacted for those patients who were lost 
to follow-up and who could not be contacted.
Data were entered into a database supported 
by Excel (Microsoft, USA). The data collected 
were subsequently analysed using SPSS 
version 21 (IBM, USA). Survival analysis was 
recorded using the Kaplan-Meier curve.
Institutional approval was obtained 
from the hospitals’ management and the 
University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BE072/13).
Results
Of the 150 patients diagnosed with breast 
cancer during 2007, 40 were ≥65 years of 
age, compatible with an incidence of 26.7%. 
All 32 patients included in the final analysis 
were women, and most (43.8%) were aged 
between 65 and 69 years (Table 1).
A significant percentage of patients were 
diagnosed at an advanced stage of their 
disease; 3.1% were diagnosed with stage 1, 
28.1% with stage 2, 31.3% with stage 3, and 
25.0% with stage 4 disease, while 12.5 % were 
incompletely staged (Table 2).
A total mastectomy was performed in 
53.0% of patients and 12.5% were treated with 
breast conservation therapy. Radiotherapy 
was administered to 40.6% of patients, chemo-
therapy to 59.4%, and hormonal therapy to 
71.8% (Table 3).
Fifteen patients were followed up with sur-
veillance mammograms. Only 6.3% (2 of 32) 
of patients received their post-treat ment sur-
veillance mammograms on time annually for 
5 years. The remaining 40.6% (13 of 32) had 
mammographic surveillance at some stage 
during the 5-year follow-up period; not annu-
ally, however, as per international recom-
mendations. The number of mammograms 
performed in this group ranged from 1 to 4 
over 5 years. With regard to mammographic 
surveillance, 18.8% (6 of 32) were non-com-
pliant, with no mammograms being per-
formed during the 5-year follow-up period, 
while 34.4% (11 of 32) were excluded, either 
owing to bilateral mastectomies or stage 4 dis-
ease at presentation. 
Of the 15 patients who were followed up 
with mammograms, either on time or delay-
ed, 26.7% (4 of 15) had new mammographic 
findings during the 5-year follow-up period. 
Of these, 1 patient had benign radiological 
findings, and 3 had malignant disease (either 
radiologically suspected or biopsy proven), 
ranging from locoregional recurrence (2 of 15) 
to a new second malignancy not related to 
breast cancer (1 of 15). 
Disease recurrence occurred in 15.6% (5 
of 32) of the total number of patients studied 
during the 5-year follow-up period. Of these 
5 patients, 3 presented with distant metas-
tases, 1 with locoregional recurrence, and 1 
with both locoregional recurrence and dis-
tant metastases detected on the same follow-
up date. With regard to mode of detection 
of recurrence, 80.0% (4 of 5) were detected 
clinically and 20.0% (1 of 5) radiologically. 
Over the 5-year follow-up, 34.4% of 
patients remained disease free, 34.4% died, 
15.6% were lost to follow-up, and 15.6% 
were classified as ‘other’. The ‘other’ category 
included patients with known metastases at 
the time of diagnosis, who had stable disease 
after 5 years of follow-up (but who were not 
disease free), or those who were seen in the 
clinic but defaulted on their mammograms 
and could not be contacted after 5 years. 
According to the Kaplan-Meier curve, the 
overall survival at 5 years was 65.6%. 
Discussion
Cancer is an emerging health problem in 
SA. The latest cancer statistics from the SA 
National Cancer Registry 2010, rank breast 
cancer as the most common cancer in women 
(20.6%), with an overall lifetime risk of 
developing the disease of 1 in 35.[1]
According to the mid-year statistics released 
by Statistics SA in July 2015, ~8.0% (4 million) 
of SA’s estimated population of almost 55 mil-
lion are documented to be ≥60 years of age. Of 
this older population, ~51.0% are female. Life 
expectancy at birth for 2015 was estimated 
at 60.6 years for males and 64.3 years for 
females, which has increased from the 2011 
statistics of 54.9 years and 59.1 years for males 
and females, respectively.[7] The proportion 
of elderly persons aged ≥60 years is therefore 
increasing over time, similar to worldwide 
trends of rising life expectancy.[8]
No previous data exist on the incidence of 
breast cancer in the elderly SA population. In 
our study, the incidence of breast cancer in 
the elderly was 26.7%, just over a quarter of all 
patients with newly diagnosed breast cancer 
during 2007. In the USA, with an estimated total 
population of 318.9 million (2014), >40.0% of 
new breast cancer cases are diagnosed in women 
>65 years of age.[9] As breast cancer incidence 
increases with age, worldwide changing 
demographics and increasing life expectancy 
are anticipated to further increase the absolute 
number of older women with breast cancer.[8]
Increasing age remains the largest single 
risk factor for the development of breast 
cancer, with ~50.0% of breast cancer cases 
occurring in women ≥65 years and >30.0% in 
women >70 years.[2] Our study demonstrated 
similar findings, with 43.8% of patients diag-
nosed at 65 - 69 years, and 44.0% at ≥75 years.
A significant percentage of patients in our 
study were diagnosed at an advanced stage 
of disease, with more than half (56.3%) pre-
senting with stage 3 and 4 disease. A total of 







Table 3. Treatment received
Treatment n (%)
Mastectomy 17 (53.0)
Breast conservation therapy 4 (12.5)
Radiotherapy 13 (40.6)
Chemotherapy 19 (59.4)
Hormonal therapy 23 (71.8)
Table 1. Age distribution
Age (years) n (%)
65 - 69 14 (43.8)
70 - 74 4 (12.5)
75 - 79 7 (22.0)
≥80 7 (22.0)
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31.2% of patients presented with stage 1 and 2 disease. Possible reasons 
include lack of healthcare information, lack of adequate screening 
programmes, socioeconomic factors, distance from healthcare centres, 
effects of comorbid conditions, and decreased mobility resulting in 
delay in seeking medical attention. This advanced stage of disease also 
impacted on treatment practices, with only 65.5% of patients receiving 
surgical management for primary breast cancer. Studies have shown 
that older patients are not treated to the same extent as younger patients, 
and increasing age at diagnosis predicts deviation from guidelines for 
all treatment modalities. Evidence-based medicine in older patients is 
lacking, as they are often excluded from clinical trials because of existing 
comorbidities and limited life expectancy.[8] Comparative studies with a 
younger cohort are needed to further define treatment practices between 
the two age groups in our setting. 
The latest practice guidelines from the American Society of Clinical 
Oncology recommend regular history-taking, physical examination, 
and yearly mammography for breast cancer follow-up.[5] No cut-off age 
for following up these patients has been defined. Yearly mammographic 
surveillance of women who have undergone curative treatment has 
been shown to be highly cost-effective because these patients are at an 
increased risk of developing a second primary breast cancer. Furthermore, 
several studies have demonstrated that such mammographic surveillance 
is associated with improved survival and a decreased breast cancer 
mortality rate in older patients with early-stage disease.[10]
Our study demonstrated poor compliance with the recommended 
international guidelines. Only 6.3% of patients were followed up 
with yearly mammograms, while in a significant percentage (40.6%) 
mammography had been delayed. Some of the reasons attributable 
for the delay were lack of referral, non-compliance with follow-up 
appointments, and limited resources.
Despite this poor compliance, new mammographic findings were 
detected in a noteworthy 26.7% of patients who underwent mam-
mography at some stage during the 5-year period. Of these patients, 
20.0% had findings of malignancy.
International figures suggest that about 30.0% of women develop 
recurrence after treatment for primary breast cancer, figures for early 
stage disease being lower.[11] The risk of new or recurrent breast cancer is 
increased among women with known disease compared with those with-
out a history of breast cancer. Karam[12] noted that the majority of breast 
cancer recurrences occur during the first decade after initial diagnosis, 
with a peak incidence 2 - 5 years after diagnosis. Surveillance is therefore 
emphasised most during the initial 5 years after therapy, when the risk of 
relapse is at its highest. Bosco et al.[13] concluded that although recurrence 
occurs in relatively few older women after 5 years, those in whom it does 
occur often have advanced cancers that are difficult to treat. To improve 
outcomes for these older women, particularly those with a ≥5-year life 
expectancy, surveillance for recurrence after 5 years of survival is essen-
tial to reduce morbidity and mortality and to maintain quality of life.
Our study demonstrated a 5-year recurrence rate of 15.6%, which is 
lower than international figures of ~30.0%. However, our figures are to 
be viewed with caution owing to the number of patients lost to follow-
up during the study. The site of recurrence, however, was comparable 
with that of international studies, with distant metastases being more 
commonly detected than locoregional recurrence in patients presenting 
with relapse. With regard to mode of detection of recurrence, the 
majority were detected clinically rather than radiologically during 
surveillance periods, similar to findings of international studies. 
Our study demonstrated that only 34.4% of patients remained 
disease free after 5 years. The remainder of patients were alive with 
metastatic disease, were lost to follow-up, or had died. 
The overall survival at 5 years was 65.6%. This figure is significantly 
lower than international figures obtained from the American Cancer 
Society and National Cancer Institute Surveillance Epidemiology and 
End Results (SEER) database, which reported a 5-year survival rate for 
breast cancer of 89.0%, a 10-year rate of 83.0%, and a 15-year rate of 78.0% 
for all stages of disease combined.[14] Our lower figures were influenced 
by the number of patients who were lost to follow-up (15.6%) and the 
significant number of patients who died (34.4%) during the follow-up 
period. Owing to poor patient records, the cause of death could not be 
determined, i.e. related to breast cancer or caused by patient comorbidity. 
Late stage of disease at diagnosis with poor follow-up practices are thought 
to be critical factors affecting the overall survival in our setting. 
Study limitations
Limitations of the study include the retrospective study design and 
the inclusion of a single centre. A further limitation is the lack of 
comparison with a younger cohort, thus not permitting any firm con-
clusions or recommendations to be made. This study will, however, 
provide the stimulus for future larger and more comparative studies 
that specifically look at outcomes and follow-up after completing 
primary breast cancer treatment. Poor patient follow-up, lack of 
adequate patient records, and lack of updated cancer registries indi-
cating patient outcomes are further limitations. 
Conclusion
Our study highlights poor compliance with internationally recom-
mended annual post-treatment mammograms in elderly patients 
diagnosed with breast cancer. Further studies with younger cohorts are 
necessary to ascertain whether this is a universal problem or unique to 
the older cohort. In patients who underwent follow-up mammograms, 
just over a quarter presented with new mammographic findings – the 
majority of these cases with features of malignancy. Health promotion 
and education are essential components of reducing the number of 
patients presenting with advanced disease, which impacts on treatment 
practices and overall survival. Further education of healthcare provid-
ers with regard to breast cancer screening and follow-up regimens 
is necessary to allow early diagnosis, standardised care, optimised 
referrals and more efficient detection of recurrence. Larger studies 
with follow-up over longer periods are required to more definitively 
assess relapse rates and relapse-specific intervals, with the objective 
of tailoring post-treatment surveillance programmes to better suit a 
resource-limited setting. 
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